<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744702</url>
  </required_header>
  <id_info>
    <org_study_id>18-003358</org_study_id>
    <nct_id>NCT03744702</nct_id>
  </id_info>
  <brief_title>Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery</brief_title>
  <official_title>Pilot Study for Determining the Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective pilot study in which the effects of ascorbic acid administration are
      investigated in adult patients undergoing cardiac surgical procedures requiring
      cardiopulmonary bypass (CPB). Ascorbic acid (Vitamin C) is an essential cofactor in the
      biosynthesis of catecholamines, and critically ill patients are known to be
      ascorbate-deficient. In addition, cardiopulmonary bypass (CPB) decreases ascorbic acid
      concentrations. Cardiac vasoplegia is the loss of vascular tone despite adequate volume
      status and cardiac output, occurring commonly in patients after CPB. This necessitates the
      administration of vasopressors and alternative agents which can have deleterious effects. The
      administration of ascorbic acid to cardiac surgical patients may improve microcirculatory
      function, enhance endogenous catecholamine levels and decrease the need for exogenous
      vasopressor support.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Specific Aims

      The investigators aim to determine the feasibility of performing a study that can assess the
      impact of ascorbic acid administration on the development and severity of cardiac vasoplegia
      in cardiac surgical patients undergoing procedures at high risk for vasoplegia.

      Specific Aim 1: Determine the feasibility of administration of high dose intravenous ascorbic
      acid in the operative and post-operative environments as well as sample size for a
      prospective, randomized, placebo controlled study.

      Specific Aim 2: Determine baseline ascorbic acid plasma levels in a small cohort of cardiac
      surgical patients.

      Specific Aim 3: Determine the impact of ascorbic acid administration on microvasculature as
      measured by dark field microscopy.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressor duration in hours</measure>
    <time_frame>Up to 10 days following surgery</time_frame>
    <description>Total duration of vasopressor therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressor dose</measure>
    <time_frame>Up to 10 days following surgery</time_frame>
    <description>Total dose of vasopressor in norepinephrine equivalents (mcg)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Vasoplegia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive ascorbic acid as this is a pilot study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Patients will receive IV ascorbic acid.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Ascor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  18 years of age or older

          -  Undergoing cardiac surgery with the use of cardiopulmonary bypass

          -  Undergoing myectomy or valve replacement/repair

        Exclusion criteria:

          -  Coronary artery bypass grafting (CABG)

          -  Circulatory arrest

          -  Active infection or sepsis

          -  Severe hepatic disease or ascites

          -  Pre-operative renal dysfunction requiring dialysis

          -  Pre-operative midodrine

          -  Pre-operative oral or intravenous steroid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica D Wittwer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Erica D. Wittwer, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vasoplegia</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>ascorbic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

